Case Study: Improving Reproducibility in GPVI‑Mediated Platelet Activation Assays Through Adoption of CRP‑A

Background

Collagen‑Related Peptides (CRPs) are widely used GPVI agonists in platelet research, yet their performance can vary depending on formulation, solubility, and handling requirements. A UK‑based research group reported persistent challenges with CRP stability and preparation, prompting an evaluation of alternative GPVI agonists. This case study summarises their experience transitioning from a conventional CRP to CRP‑A and the resulting impact on assay reproducibility, workflow efficiency, and user confidence.

Challenges With Conventional Collagen‑Related Peptides

Solubility and Handling Issues

During routine platelet activation experiments, the group observed that their previous CRP frequently precipitated during serial dilutions. The peptide required continuous vortexing — during preparation, dispensing, and sometimes even between samples — to maintain solubility. This behaviour was unpredictable and difficult to control, particularly when processing large batches of time‑sensitive samples.

Impact on Experimental Reproducibility

The instability of the reagent introduced substantial variability between donors, even at maximal concentrations. Flow cytometry often produced inconsistent data unsuitable for publication, with no clear mechanistic explanation for the poor quality. For less experienced researchers, the steep learning curve associated with CRP preparation increased the likelihood of technical error and reduced confidence in the assay.

Consequences for Workflow and Training

The group’s response to these challenges was fragmented. Some researchers avoided CRPs entirely and switched to alternative GPVI agonists such as convulxin, while others continued using CRPs after developing personal preparation strategies. This divergence created methodological inconsistency, hindered standardisation, and complicated the training of new laboratory members.

Transition to CRP‑A

Rationale for Evaluation

CRP‑A was first encountered at EUPLAN 2023, where preliminary data indicated comparable platelet aggregation and flow cytometry responses to other CRPs, with effective concentrations in the low µg/mL range. The reagent was also approximately 30% more cost‑effective, prompting the group to trial it as a potential replacement.

Initial Testing

Following rapid delivery, CRP‑A was reconstituted in acetic acid and evaluated in standard platelet aggregation and flow cytometry assays. Activation profiles were consistent with those obtained using the previous CRP. However, the key differentiator was solubility: CRP‑A remained in solution throughout preparation and use, eliminating the need for continuous vortexing.

Outcomes

Improved Stability and Ease of Use

CRP‑A’s ability to remain in solution under routine laboratory conditions removed a major source of stress and uncertainty from assay preparation. Researchers no longer needed to interrupt workflows to re‑vortex samples, reducing the risk of timing‑related artefacts.

Enhanced Reproducibility

The group reported markedly improved consistency between donors and between reagent lots. The simplified preparation protocol reduced operator‑dependent variability, leading to more reliable aggregation and flow cytometry data.

Standardisation Across the Research Team

Because CRP‑A required no specialised handling techniques, all members of the group — including new trainees — were able to prepare the reagent confidently. This facilitated methodological alignment across the team and improved the overall quality and comparability of experimental results.

Conclusion

The transition from a conventional Collagen‑Related Peptide to CRP‑A significantly improved the reproducibility, stability, and usability of GPVI‑mediated platelet activation assays within this research group. CRP‑A’s enhanced solubility profile eliminated a major source of technical variability, enabling standardised workflows and more reliable data generation. Its cost advantage further strengthened its suitability as a long‑term replacement for traditional CRPs.